AGP Picks
View all

North Carolina Wellness News
Provided by AGP

North Carolina Wellness News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on North Carolina Wellness News.

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

November 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30

Press releases published on November 9, 2026

Prime Medicine to Present at Jefferies Global Healthcare Conference
an hour ago

Prime Medicine to Present at Jefferies Global Healthcare Conference

Indeterminate GlobeNewswire
Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update
an hour ago

Compass Therapeutics Reports 2026 Third Quarter Financial Results and Provides Corporate Update

Indeterminate GlobeNewswire
The MUHC Foundation’s second annual Breakthrough Run raises $289,676 to advance research and patient care
an hour ago

The MUHC Foundation’s second annual Breakthrough Run raises $289,676 to advance research and patient care

Indeterminate GlobeNewswire
La deuxième édition de la Course vers la Percée de la Fondation du CUSM recueille 289 676 $ pour faire avancer la recherche et les soins aux patient(e)s
an hour ago

La deuxième édition de la Course vers la Percée de la Fondation du CUSM recueille 289 676 $ pour faire avancer la recherche et les soins aux patient(e)s

Indeterminate GlobeNewswire
The Fur Flies Again: Global Cutest Pets Showdown Returns for Round Two!
an hour ago

The Fur Flies Again: Global Cutest Pets Showdown Returns for Round Two!

Indeterminate GlobeNewswire
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026
an hour ago

Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026

Indeterminate GlobeNewswire
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
an hour ago

Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease

Indeterminate GlobeNewswire
Mentari Therapeutics to Present at Upcoming Investor Conferences
an hour ago

Mentari Therapeutics to Present at Upcoming Investor Conferences

Indeterminate GlobeNewswire
BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop
an hour ago

BioVie Presents New Biomarker Data from the ADDRESS-LC Trial of Bezisterim in Long COVID at the NIH RECOVER-TLC Third Annual Workshop

Indeterminate GlobeNewswire
Mereo BioPharma Reports Third Quarter 2026 Financial Results
an hour ago

Mereo BioPharma Reports Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire
Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT
an hour ago

Achieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUIT

Indeterminate GlobeNewswire
Iambic to participate in Jefferies Global Healthcare Conference
an hour ago

Iambic to participate in Jefferies Global Healthcare Conference

Indeterminate GlobeNewswire
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
an hour ago

AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450

Indeterminate GlobeNewswire
Adneuris Therapeutics Reaches Key Regulatory Milestone with FDA Submission of New Drug Application for Cebranopadol in Moderate-to-Severe Acute Pain
an hour ago

Adneuris Therapeutics Reaches Key Regulatory Milestone with FDA Submission of New Drug Application for Cebranopadol in Moderate-to-Severe Acute Pain

Indeterminate GlobeNewswire
Neutrolis Doses First Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in Phase 1b LIBERATE-I Trial of NTR-1011 and Will Present Phase 1a Data at ACR Convergence 2026
an hour ago

Neutrolis Doses First Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in Phase 1b LIBERATE-I Trial of NTR-1011 and Will Present Phase 1a Data at ACR Convergence 2026

Indeterminate GlobeNewswire
Tectonic Therapeutic to Participate in Upcoming Investor Conferences
an hour ago

Tectonic Therapeutic to Participate in Upcoming Investor Conferences

Indeterminate GlobeNewswire
Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026
an hour ago

Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026

Indeterminate GlobeNewswire
ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
an hour ago

ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference

Indeterminate GlobeNewswire
R1 and Ascension Extend Partnership Through 2037 Leveraging Phare OS to Advance a Technology-First Revenue Cycle
an hour ago

R1 and Ascension Extend Partnership Through 2037 Leveraging Phare OS to Advance a Technology-First Revenue Cycle

Indeterminate GlobeNewswire
Eos SENOLYTIX’s PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference
an hour ago

Eos SENOLYTIX’s PTC-2105 Reduced Semaglutide-Associated Lean-Mass Loss in Aged Mice: Data to Be Presented at 19th Sarcopenia, Cachexia & Wasting Disorders International Conference

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

North Carolina Wellness News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.